Agenus shared a post on LinkedIn:
“Access matters—especially when standard options have been exhausted.
France has expanded national compassionate access to BOT+BAL, enabling fully reimbursed, hospital-based access across three hard-to-treat solid tumors under a single, nationally standardized AAC protocol.
This update extends access beyond colorectal cancer to include platinum-resistant ovarian cancer and advanced soft-tissue sarcomas—diseases with substantial unmet medical need and historically limited responsiveness to immunotherapy.
We are encouraged by France’s continued leadership in enabling responsible early access while maintaining rigorous oversight and real-world evidence collection.
For patients, clinicians, and families navigating limited options, this expansion represents another meaningful step forward.”
You can also read: France Expands Reimbursed Compassionate Access for Botensilimab/Balstilimab to Ovarian Cancer and Soft-Tissue Sarcomas
